Table 1.

European LeukemiaNet recommendations for BCR-ABL1 kinase domain mutation analysis[7]

At diagnosis

Only in accelerated phase or blast crisis patients

During first-line imatinib therapy

In case of treatment failure

In case of an increase in BCR-ABL1 transcript levels leading to loss of major molecular response

In any other case of suboptimal response

During second-line dasatinib or nilotinib therapy

In case of hematologic or cytogenetic failure

Disease progression to accelerated or blast phase